Submitted for Publication: August 28, 2014; final revision received and accepted January 26, 2015.
Published Online: May 27, 2015. doi:10.1001/jamapsychiatry.2015.0111.
Study concept and design: Schmidt, Nieman, Rubinow.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Schmidt, Martinez, Harsh, Thompson, Rubinow.
Critical revision of the manuscript for important intellectual content: Schmidt, Ben Dor, Guerrieri, Koziol, Nieman, Rubinow.
Statistical analysis: Schmidt, Ben Dor, Harsh, Koziol, Rubinow.
Obtained funding: Schmidt.
Administrative, technical, or material support: Schmidt, Ben Dor, Guerrieri, Harsh, Thompson, Rubinow.
Study supervision: Schmidt, Martinez, Rubinow.
Conflict of Interest Disclosures: This work was written as part of the official duties of Peter J. Schmidt, MD, as a government employee.
Funding/Support: This research was supported by the Intramural Research Program of the National Institute of Mental Health (NIMH), National Institutes of Health (NIH). Novartis Pharmaceuticals supplied estradiol skin patches (Vivelle-Dot) and matched placebos for this study.
Role of the Funder/Sponsor: The NIMH, NIH, and Novartis Pharmaceuticals had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: The views expressed in this article do not necessarily represent the views of the NIMH, NIH, Department of Health and Human Services, or the US government.
Additional Contributions: Linda Schenkel, BS (Section on Behavioral Endocrinology, NIMH, NIH, Department of Health and Human Services), provided data management support. There was no financial compensation.